Daniel J Lodge Selected Research

Methylazoxymethanol Acetate

1/2021	Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia.
1/2020	Developmental alterations in the transcriptome of three distinct rodent models of schizophrenia.
1/2019	Effect of estrous cycle on schizophrenia-like behaviors in MAM exposed rats.
1/2018	Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility.
1/2017	Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia.
1/2016	Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.
9/2014	An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.
7/2014	Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia.
1/2013	The MAM rodent model of schizophrenia.
2/2012	Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel J Lodge Research Topics

Disease

31	Schizophrenia (Dementia Praecox) 01/2021 - 07/2006
12	Psychotic Disorders (Schizoaffective Disorder) 01/2021 - 10/2007
4	Substance-Related Disorders (Drug Abuse) 01/2022 - 05/2007
2	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 01/2022
2	Pain (Aches) 01/2022 - 01/2022
2	Mental Disorders (Mental Disorder) 02/2012 - 05/2011
1	Neonatal Abstinence Syndrome 01/2022
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2021
1	Hallucinations (Hallucination) 01/2020
1	Neurodevelopmental Disorders 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2020
1	Autistic Disorder (Autism) 01/2018
1	AIDS-Related Complex (ARC) 05/2017
1	Neurobehavioral Manifestations 05/2017
1	Cognitive Dysfunction 05/2017
1	Shock 09/2015
1	Treatment-Resistant Depressive Disorder 07/2014
1	Epilepsy (Aura) 07/2014
1	Infections 05/2011
1	Parkinson Disease (Parkinson's Disease) 08/2010
1	Dyskinesias (Dyskinesia) 08/2010

Drug/Important Bio-Agent (IBA)

22	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 07/2006
13	Methylazoxymethanol AcetateIBA 01/2021 - 10/2008
5	Pharmaceutical PreparationsIBA 01/2022 - 10/2008
4	ParvalbuminsIBA 10/2019 - 02/2009
4	Amphetamine (Amfetamine)FDA LinkGeneric 01/2017 - 10/2007
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2017
3	Antipsychotic Agents (Antipsychotics)IBA 01/2020 - 11/2012
3	CannabinoidsIBA 01/2018 - 10/2014
2	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2022
2	Orexin ReceptorsIBA 01/2021 - 01/2021
2	OrexinsIBA 01/2021 - 01/2021
2	Ketamine FDA LinkGeneric 01/2020 - 05/2017
2	Poly I-CIBA 01/2020 - 01/2018
2	Dronabinol (THC)FDA LinkGeneric 02/2016 - 10/2014
2	EndocannabinoidsIBA 02/2016 - 10/2014
1	Drug CombinationsIBA 01/2022
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2022
1	suvorexantIBA 01/2021
1	Orexin Receptor AntagonistsIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2020
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 10/2019
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2019
1	Biological ProductsIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018
1	Antidepressive Agents (Antidepressants)IBA 05/2017
1	Therapeutic UsesIBA 05/2017
1	Phencyclidine (Angel Dust)IBA 02/2016
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 02/2016
1	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 02/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	N- succinimidyl- 3- (2- pyridyldithio)butyrateIBA 09/2015
1	anandamide (arachidonylethanolamide)IBA 10/2014
1	Acetates (Acetic Acid Esters)FDA Link 07/2014
1	gamma-Aminobutyric Acid (GABA)IBA 01/2014
1	Glutamic Acid (Glutamate)FDA Link 01/2014
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 11/2012
1	Chloral HydrateIBA 02/2012
1	Dopamine Agonists (Dopamine Agonist)IBA 05/2011
1	Levodopa (L Dopa)FDA LinkGeneric 08/2010

Therapy/Procedure

4	Therapeutics 01/2017 - 05/2011
1	Precision Medicine 01/2020
1	Vagus Nerve Stimulation 07/2014
1	Deep Brain Stimulation 07/2013